BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:BIO3 - DE0005227235
BIO3.DE Key Statistics, Chart & Performance
The current stock price of BIO3.DE is 30 EUR. In the past month the price increased by 15.38%. In the past year, price decreased by -23.66%.
BIO3.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BIO3.DE. When comparing the yearly performance of all stocks, BIO3.DE is a bad performer in the overall market: 87.75% of all stocks are doing better.
BIO3.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE. BIO3.DE has only an average score on both its financial health and profitability.
BIO3.DE Financial Highlights
Over the last trailing twelve months BIO3.DE reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -117.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| Debt/Equity | 1.26 |
BIO3.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 1600% and a revenue growth 11.95% for BIO3.DE
BIO3.DE Ownership
About BIO3.DE
Company Profile
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Company Info
BIOTEST AG-VORZUGSAKTIEN
Landsteinerstr. 5
Dreieich HESSEN DE
Employees: 2495
Phone: 4961038010
BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ
What does BIOTEST AG-VORZUGSAKTIEN do?
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Can you provide the latest stock price for BIOTEST AG-VORZUGSAKTIEN?
The current stock price of BIO3.DE is 30 EUR.
Does BIOTEST AG-VORZUGSAKTIEN pay dividends?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a dividend yield of 0.09%. The yearly dividend amount is currently 0.04.
What is the ChartMill technical and fundamental rating of BIO3 stock?
BIO3.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for BIOTEST AG-VORZUGSAKTIEN?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) operates in the Health Care sector and the Biotechnology industry.
Would investing in BIOTEST AG-VORZUGSAKTIEN be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIO3.DE.
What is the market capitalization of BIO3 stock?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a market capitalization of 1.19B EUR. This makes BIO3.DE a Small Cap stock.